Privia Health Group, Inc. current report, 31 July 2023

Full document

Privia Health Group, Inc. — Form 8-K Summary

Business context and reporting period

Privia Health Group, Inc. filed this Current Report on Form 8-K on July 31, 2023, under Items 5.02, 5.03, and 9.01. The filing reports board changes and amendments to the Company’s bylaws. The reported actions became effective August 1, 2023, except where otherwise noted.

Board and governance changes

  • The Board increased from 10 to 11 directors and elected David Wichmann as a Class I director and Pamela Kimmet as a Class III director, effective August 1, 2023.
  • Jeffrey Bernstein resigned from the Board and as chair of the Compensation Committee and Nominating and Corporate Governance Committee following Goldman Sachs’ sale of its ownership position through a secondary offering completed May 8, 2023. The resignation was not due to disagreement with the Company.
  • Pamela Kimmet was appointed chair of the Compensation Committee. David King became chair of the Nominating and Corporate Governance Committee, and Nancy Cocozza joined that committee.
  • The Board determined that Mr. Wichmann and Ms. Kimmet are independent under Nasdaq standards; Ms. Kimmet also satisfies the heightened independence standard applicable to Compensation Committee members.

Compensation and ownership

  • Each newly elected director will receive the annual cash retainer specified in the Company’s Non-Employee Director Compensation Program.
  • Each will also receive an annual restricted stock unit grant with a grant-date fair value of $200,000, prorated through the next annual stockholders’ meeting.
  • Mr. Wichmann is co-founder of Jory Capital. As of July 28, 2023, Jory Capital owned 1,315,340 Company shares, representing approximately 1% of outstanding common stock.

Bylaw amendments and other matters

  • The Board approved Third Amended and Restated Bylaws effective August 1, 2023.
  • The amended bylaws permit the Board to expand from 11 to as many as 15 directors and remove the office of president from the bylaws.
  • The filing includes the amended bylaws, a July 31, 2023 press release, and the Inline XBRL cover page as exhibits.

Financial metrics, outlook, and risks

This filing does not provide revenue, profit, cash flow, margins, debt, liquidity, financial guidance, or operating outlook. It does not report a new financial contingency or unusual financial item. The principal disclosed governance consideration is the leadership transition following Goldman Sachs’ secondary offering and the related board and committee changes.

Important facts for investors to verify

  • Confirm the effective dates and final composition of the Board and its committees.
  • Review the Third Amended and Restated Bylaws for the expanded board-size limit and removal of the president position.
  • Assess the dilution and expense implications of the prorated restricted stock unit grants to the new directors.
  • Review subsequent filings for any additional board changes, ownership changes involving Jory Capital, or financial guidance not included in this 8-K.